+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07165132

Phase 1 Study of RYZ401, a Radiopharmaceutical Therapy with Actinium-225, for Neuroendocrine and Other Solid Tumors Expressing Somatostatin Receptors

Led by RayzeBio, Inc. · Updated on 2026-11-03

104

Participants Needed

15

Research Sites

321 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating RYZ401, a novel radiopharmaceutical therapy labeled with Actinium-225, in adults with neuroendocrine tumors NETs and other solid tumors that express somatostatin receptors SSTRs. This Phase 1 first-in-human study aims to determine the recommended Phase 2 dose, identify the optimal treatment regimen, characterize safety and tolerability, and assess preliminary efficacy of RYZ401 in these patients. The focus is on metastatic or locally advanced and unresectable tumors from various primary sites, including gastrointestinal, pancreatic, lung, thyroid, breast, urogenital, and adrenal tumors. Participants receive RYZ401 in a dose-escalation phase to find the best dose, followed by a dose-expansion phase where groups receive treatment based on tumor type and SSTR expression. The therapy is administered sequentially, and SSTR-positivity is confirmed through PET imaging before treatment. Adequate kidney, blood, and liver function are required for participation, and the study excludes those with prior similar radiopharmaceutical therapies, organ transplants, or certain medical conditions. Throughout the study, participants are monitored for dose-limiting toxicities in the first four weeks of treatment and are followed up through at least six weeks after the initial treatment cycle. Safety, tolerability, and preliminary effectiveness are evaluated through clinical assessments, imaging, and laboratory tests. The trial may last until 2033, with primary completion expected by 2027, involving careful long-term follow-up to understand treatment impact and patient outcomes.

CONDITIONS

Brief Title

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Research Team

R

RayzeBio Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here